A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 191
- Population
- ALL · 55 Years
- Duration
- 2011-06-01 to 2016-04-01
- Intervention
- GSK933776; Placebo
- Comparator
- Placebo
- Outcomes measured
- Change From Baseline in the Area of Geographic Atrophy (GA) Assessed by Color Fundus Photographs (FP) in the Study Eye…; Number of Participants With Ocular or Non-ocular Adverse Events (AEs) During the Treatment Period — Up to 21 months; Number of Participants With Ocular or Non-ocular Serious Adverse Events (SAEs) During the Treatment Period — Up to 21 m…; Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Systolic Bl…; Number of Participants With Vital Signs of Potential Clinical Importance (PCI) During the Treatment Period: Heart Rate…; Number of Participants With 12-lead Electrocardiogram (ECG) of Potential Clinical Importance (PCI) — Baseline, Month 6,…; Number of Participants With Abnormal Laboratory Parameter Values of Potential Clinical Importance (PCI) — At any point…; Number of Participants With Abnormal Magnetic Resonance Imaging (MRI) — Month 2, Month 3, Month 4, Month 6, Month 12, M…; Change From Baseline in Area of GA Assessed by Fundus Autofluorescence Images (hypoAF) Corresponding to GA in Study Eye…; Change From Baseline in Area of Total hypoAF in Study Eye — Baseline, 6 months, 12 months and 18 months; Number of Participants Losing Letters in Early Treatment Diabetic Retinopathy Study (ETDRS)-Best Corrected Visual Acuit…; Mean Change in ETDRS-BCVA Score From Baseline at Every Month up to Month 18 — Baseline and every month up to Month 18; Area Under the Plasma Concentration-time Curve From Time 0 to the End of Dosing Interval at Steady-state (AUC0-28d) of…; Maximum Observed Plasma Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Cta…; Clearance (CL) of GSK933776 in Geographic Atrophy Participants — Day 56, Day 63, 70 or 77, Day 84, Day 112, Day 140, Da…; Estimation of Terminal Phase Half-life (T1/2) of GSK933776 in Geographic Atrophy Participants — Day 56, Day 63, 70 or 7…; Volume of Distribution at Steady-state (Vdss) of GSK933776 in Geographic Atrophy Participants Estimated From Population…; The Pharmacodynamic Effects of GSK933776 Total (Bound and Unbound) Plasma Total Amyloid Beta (Abeta42), and Amyloid Bet…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.